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CD7, a molecule normally expressed on 90% of nor-
mal CD4+ T cells, is often de®cient on the malignant
T cells of cutaneous T cell lymphoma. To investigate
the clinical and biologic implications of CD7 expres-
sion, blood lymphocytes from 42 patients with the
leukemic phase of cutaneous T cell lymphoma
(CD4/CD8 ratio of 10 or more with evidence of a T
cell clone in the blood) were analyzed for level of
expression of CD7 by ¯ow cytometry. CD7 expres-
sion by cells did not clearly segregate into two dis-
tinct subgroups that are either CD7 positive or CD7
negative as generally thought; however, nine of 17
patients with a predominantly CD4+CD7+ tumor
population on early studies became CD4+CD7± over
time whereas the converse situation was not
observed. In addition, of three patients with evidence
of large tumor cells in the blood coexisting with
smaller cells, discordant CD7 expression was
observed in one instance. In lymph node specimens,
the percentage of cells expressing CD7 and other T
cell markers did not correlate with histologic evid-
ence of involvement. CD7 expression on blood lym-
phocytes also did not correlate with patients' survival
nor to serum IgE levels or blood eosinophil counts, a
®nding suggesting that this marker does not identify
functional cell subsets that produce serum inter-
leukin-4 or -5, respectively. We speculate that the
level of CD7 expression on malignant T cells may be
the effect of sustained antigen stimulation in vivo
analogous to what has been proposed to occur with
normal T cells during aging. Key words: CD4/¯ow
cytometry/Th2. J Invest Dermatol 117:654±662, 2001
S
eÂzary syndrome (SS) is an erythrodermic and leukemic
variant of cutaneous T cell lymphoma (CTCL) (Lutzner
et al, 1975; Diamandidou et al, 1996). Traditionally, the
diagnosis of SS is based on evidence of increased numbers
of atypical lymphocytes with cerebriform nuclei (SeÂzary
cells) in the blood (Winkelmann and Linman, 1973; Flandrin and
Brouet, 1974). The malignant T cells of SS have been characterized
to be mature ``memory'' helper T cells [T cell receptor (TCR)-
ab+, CD2+, CD3+, CD4+, CD5+, CD8±, CD45RO+] that are
often de®cient in CD7 expression (Haynes et al, 1981; Bogen et al,
1996; Harmon et al, 1996; Bernengo et al, 1998), occasionally
exhibit decreased expression or loss of one or more pan T cell
markers (Harmon et al, 1996; Bernengo et al, 1998), and are clonal
by molecular genetics techniques (Weiss et al, 1989; Bakels et al,
1991; Whittaker et al, 1991; Zelickson et al, 1991; Weinberg et al,
1995; Russell-Jones and Whittaker, 1999) or by chromosome
analysis (Whang-Peng et al, 1976; Nowell et al, 1982; Johnson et al,
1985; Thangavelu et al, 1997).
Most patients with SS develop erythroderma and SeÂzary cytemia
shortly after the onset of the disease, but the salient features of SS
may occur later in the course of disease following a prodrome of
pruritus, nonspeci®c dermatitis, erythroderma without de®nite
hematologic involvement, or in patients previously diagnosed to
have mycosis fungoides (MF) (Clendenning et al, 1964; Schein et al,
1976; Buechner and Winkelmann, 1983; Bowen et al, 1995). In
addition, occasional patients with extensive plaque or tumor phase
MF have large numbers of SeÂzary cells in their blood (Flandrin and
Brouet, 1974; Schein et al, 1976), but such patients are not usually
designated as SS because of the absence of erythroderma. In this
study, we include all patients with CTCL who manifest the blood
®ndings of SS (de®ned herein as numerous SeÂzary cells in the
blood, increased numbers of T cells with high CD4/CD8 ratio, and
evidence of T cell clonality).
CD7 is a 40 kDa glycoprotein member of the immunoglobulin
gene superfamily that is expressed on 85±90% of normal adult
peripheral blood T cells (almost all CD8+ T cells and approximately
90% of CD4+ T cells) (Reinhold et al, 1993). It also is expressed on
most natural killer cells (Rabinowich et al, 1994). Within the CD4+
T cell population, CD7 is expressed on almost all CD45RA+
``naive'' T cells, and divides the CD45RA± ``memory'' T cells into
CD7+ and CD7± subsets (Reinhold et al, 1993). Reinhold et al
(1996; Reinhold and Abken, 1997) have provided evidence that
normal CD4+CD7± cells are derived from CD4+CD7+ precursors
by differentiation during the late immune response. Functionally,
CD7 is thought to be involved in signal transduction (Lazarovits
et al, 1994; Leta et al, 1995) or integrin-mediated adhesion (Shimizu
et al, 1992). The natural ligand of CD7 is still unknown.
The atypical lymphocytes present in tissue in®ltrates and blood of
CTCL are frequently de®cient in CD7 expression, and this has
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been used for diagnostic purposes (Wood et al, 1986; Harmon et al,
1996; Bergman et al, 1998). The percentage of CD4+CD7± cells
also correlates well with SeÂzary cell counts in some series
(Vonderheid et al, 1994; Laetsch et al, 2000). It is unclear whether
the increase in CD4+CD7± cells in CTCL is the result of an
aberrant loss of CD7 expression by malignant T cells or the result of
neoplastic expansion of a cell population that is CD4+CD7±. In
support of the latter hypothesis, a small population of CD4+CD7±
cells with cerebriform nuclei has been identi®ed in the blood of
normal individuals (Matutes et al, 1983).
Th1 and Th2 lymphocyte subsets based on cytokine secretion
pro®les were ®rst described in mice by Mosmann et al (1986), and
subsequently in human T cell clones by Romagnani (1991). CD4+
T helper lymphocytes and other immune cells that produce
interleukin (IL)-2, interferon (IFN)-g, tumor necrosis factor
(TNF)-b), and IL-12, preferentially favor development of cellular
immune responses; these Th1-like cells are referred to collectively
as type 1 cytokine producing cells (Abbas et al, 1996; Lucey et al,
1996). CD4+ T helper and other cells that produce IL-4, IL-5,
IL-6, IL-10, and IL-13, provide help for antibody production;
these Th2-like cells are referred to as type 2 cytokine producing
cells. In this regard, IL-4 and IL-13 facilitates the isotype switch by
B cells to produce IgE, and IL-5 activates eosinophils. In humans,
the Th1 and Th2 cell dichotomy is not as apparent as in mice
because the majority of T cell clones can produce IFN-g together
with IL-4 or IL-10. These Th0 cells have an intermediate cytokine
pro®le with release of IL-2, IL-4, IL-5, and IFN-g, and might
represent a transient state before Th1 or Th2 cell differentiation
(Autran et al, 1995).
In most cases of SS, malignant cells on stimulation produce lower
IL-2 and IFN-g and higher IL-4 or IL-5, i.e., a cytokine pro®le that
typi®es the Th2 subset of T helper cells (Vowels et al, 1992; Borish
et al, 1993; Saed et al, 1994; Tendler et al, 1994), and this
presumably contributes to the immunode®ciency, hypereosino-
philia (via IL-5), and elevated serum IgE levels (via IL-4 and IL-13)
that often occurs in SS (Rook and Heald, 1995). In one case of SS,
however, in which the tumor cell immunophenotype was
CD4+CD7+, the cells produced the Th1 cytokines IL-2 and
IFN-g, but not IL-4 (Yagi et al, 1996). It was suggested that cases of
SS with the CD4+CD7+ phenotype may be examples of the Th1
subset.
In this study, we present our experience with SS and related
leukemic expressions of CTCL in terms of the clinical importance
of CD7 expression on circulating malignant T cells.
MATERIALS AND METHODS
Single color ¯ow immunophenotyping of peripheral blood lymphocytes
was performed using a panel of murine monoclonal antibodies purchased
from Becton-Dickinson (San Jose, CA) and Ortho Diagnostics (Raritan,
NJ): T cell markers CD2 (anti-Leu5), CD3 (anti-Leu4), CD4 (anti-
Leu3), CD5 (anti-Leu1), CD7 (anti-Leu9), CD8 (anti-Leu2); B cell
markers CD19 (anti-Leu12), CD20 (anti-Leu16), anti-k, anti-l; activ-
ation markers HLA-DR, CD25 (anti-IL2Ra), CD71 (anti-transferrin
receptor), CD38 (anti-OKT10); and natural killer cell-associated markers
CD16 (anti-Leu11), CD56 (anti-Leu19), and CD57 (anti-Leu7). For data
analysis, the percentage of CD16+ cells was used to signify the percent-
age of natural killer cells in samples. Quantitative SeÂzary cell counts
(number of SeÂzary cells per 100 lymphocytes on blood smear), chromo-
some analysis, Southern blot and polymerase chain reaction/denaturing
gradient gel electrophoresis molecular studies were performed using
methods that were previously reported (Nowell et al, 1982; Vonderheid
et al, 1985; Weinberg et al, 1995). Other laboratory tests were performed
using standard procedures.
Patients Forty-two patients with CTCL and evidence of blood
involvement were studied (Table I). Patients were selected on the basis
of immunophenotypic evidence of an expanded CD4+ T cell population
with high CD4/CD8 ratio (> 10) on at least one study, blood ®ndings
recently advocated to be a useful diagnostic criterion for SS (Willemze
et al, 1997); however, for patient nos 13 and 41, the tumor cell
phenotype was CD2+CD3+CD4±CD8± (the cells of patient 41 also
reacted with antibody directed against the ab TCR complex and not gd
TCR determinants, indicating that these cells were not derived from
TCR-gd+ T cells). The malignant T cell phenotype of four other
patients was CD2±CD3+CD4+CD8± (nos 4, 9, 32, and 42) and
CD2+CD3±CD4+CD8± in one patient (no. 25). All patients had
extensive skin involvement, which was manifested as generalized or
nearly generalized erythroderma in 35 patients, disseminated plaques in
®ve patients (nos 5, 13, 15, 27, and 29), diffuse brownish
hyperpigmentation with associated sarcoidal granulomatous in¯ammation
in patient 11 (Gregg et al 2000), and mild erythema with features of
granulomatous slack skin disease in one patient (no. 20). Of the 35
patients diagnosed to have SS, the erythroderma and characteristic blood
®ndings were preceded by lesions more typical of MF in four patients
(nos 18, 25, 36, and 39) and, therefore, may be considered to be
examples of secondary SS rather than classic SS in which erythroderma
begins de novo. Lymph node (LN) biopsies were performed on 33
patients; however, ¯ow immunophenotyping was available on only 24
specimens (Table II). Two LN specimens were obtained at different
times during the course of disease in two patients (nos 9 and 21), and in
patient 39, ¯ow studies were performed on a ®ne needle aspirate. LN
were classi®ed from LN1 to LN4 based on the number of atypical
lymphoid cells in paracortical zones and the degree of distortion of LN
architecture as described by Sausville et al (1985). The pathologic
diagnosis was dermatopathic lymphadenopathy (LN1±2 rating) in six LN
specimens, lymphoma (LN3±4 rating) in 17 specimens, and
granulomatous in¯ammation in the LN from patient 11 with sarcoidal
granulomatous features in the skin. In the 14 nodal specimens with
evidence of partial or diffuse effacement of architecture by malignant
cells (LN4 rating), the morphologic appearance of the malignant cells
was a small cerebriform cell predominant in seven LN, mixed small±large
cell pattern in four LN, and a large cell predominate pattern in three
LN.
Thirty-six of the patients were Caucasian (15 men, 21 women) and
six were African-American (two men, four women). The median age at
the time of study was 72.5 y (range, 31±90 y), and the median duration
from onset of disease to the time of study was 38 mo (range, 4±334 mo).
All patients had quantitative SeÂzary cell counts exceeding 15% of
lymphocytes on blood smears (median, 45%; range, 17±92%) with an
absolute SeÂzary count that exceeded 1000 per mm3 in 26 (62%) patients.
Evidence of T cell clonality was shown in the blood by Southern blot,
polymerase chain reaction or chromosome analysis in 22 of 27 (81%), 22
of 25 (88%), and 40 of 42 (95%) studied, respectively. The presence of a
T cell clone was shown by at least one method in all patients, and by
two or more methods in all but three patients (nos 3, 28, and 33). All 39
patients screened for antibody against type I human T lymphotropic
virus had a negative test result, including the six African-American
patients (testing not performed on patients 8, 29, and 39).
To con®rm our results, we also analyzed the expression of CD7 by
circulating malignant T cells from patients with SS studied at the
University of Turin (Bernengo et al, 1998). At this center, the diagnosis
of SS is based on the presence of generalized erythrodermic CTCL and
SeÂzary cell counts > 10% of blood leukocytes and absolute counts > 1000
cells per mm3. For comparison with our patients, 27 patients with a
(CD3+CD4+)/(CD3+CD8+) ratio > 10 were selected for analysis.
Statistical analysis Because some of the data did not have a normal
distribution, i.e., failed the normality test of Kolmogorov±Smirnov, the
p-values of nonparametric tests are reported herein for most analyses, but
in some instances when nonparametric testing showed a marginal level of
signi®cance, signi®cant differences among groups could be con®rmed
with parametric tests using transformed data that had a normal
distribution, e.g., log (%CD57) and log (%CD38) instead of raw %CD57
and raw %CD38, respectively. To adjust for the contribution of CD7+
non-CD4+ cells on total CD7 expression, CD7 values were corrected by
subtracting the percentage of CD8+ T cells and CD16+ natural killer cells
from the percentage of CD7 for each case, and the level of CD7
expression by CD4+ cells was estimated by dividing the corrected CD7
value by CD4. Two patients with CD4± tumor cells were excluded from
this calculation. The validity of this calculation as an estimate of the level
of CD7 expression by CD4+ cells was shown by the strong inverse
correlation between the calculated CD7 level with the percentage of
CD4+CD7± cells that were directly measured by two-color immuno-
phenotyping in seven of the more recently studied patients in this series
(rho = ±0.991, p < 0.001) and in 12 patients studied at the University of
Turin (rho = ±0.732, p < 0.001). The correlation between number of
CD7+ cells and other continuous laboratory measurements was examined
using the Spearman rank order correlation test. Differences in laboratory
studies between patients grouped according to relatively low (< 50%) and
high (> 50%) CD7 expression on CD4+ lymphocytes were tested using
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the nonparametric Mann±Whitney test, but also the parametric Student's
T-test when appropriate. The Fisher's exact test and Pearson c2-square
test for 2 3 2 tables and R 3 C tables, respectively, were used as
measures of association among categorized clinical and laboratory
parameters. Kaplan±Meier and the Cox proportional hazards regression
model were used to test for variables that have prognostic signi®cance.
Log-rank and Gehan tests were used to detect survival differences
between groups. Statistical software used for data analysis were SYSTAT for
Windows, Version 8 (SYSTAT, Evanston, IL), SigmaStat for Windows,
Version 2 (Jandel Scienti®c Software, San Rafael, CA), and EGRET
(Statistics and Epidemiology Research, Seattle, WA).
RESULTS
The percentage of CD4+ cells in our patients with leukemic phase
CTCL was increased above the normal range for single color ¯ow
immunophenotyping for our laboratory (i.e., 35% to 55%) in all
patients excluding two patients with a CD3+CD4±CD8± tumor cell
phenotype. The mean percentage of CD4+ cells for the CD4+ cases
was 83.0% 6 9.7% (mean 6 SD; range, 55±99%), and the mean
percentage of CD8+ cells for all cases was correspondingly low
(4.4% 6 2.5%, mean 6 SD). Of interest, the percentage of CD3+
cells was increased above the normal laboratory range (i.e., 68±
82%) in only 30 of 41 (73%) patients, excluding one patient with an
aberrant loss of CD3 (mean %CD3 6 SD, 86.2% 6 8.1%; range,
67±98%). This suggests that as the proportion of malignant CD4+
cells increases in the blood of SS, normal CD4+ and CD8+ cells
decrease in tandem before the total CD3+ cell population increases.
The percentage of natural killer cells in these patients as assessed by
CD16 and CD57 was also low (mean %CD16 6 SD, 4.6 6 3.9
Table I. Concurrent laboratory data in patients with the leukemic phase of CTCLa
PT A/R/S DX DURb
Stage
(TN rating) WBC LY EO SZ CD3 CD4 CD8 CD7 IgE LDH LSc
1 87/W/F SS 24 III (T4N1) 84.6 70 4f 64 92 73 2.0 6 Ð 607 D
2 59/B/M SS 36 III (T4N1) 13.5 54 5f 44 82 88 1.0 6 527 327 D
3 88/W/F SS 10 IVa (T4N3) 33.1 56 1f 30 91 89 5.0 7 2 386 D
4 70/W/F SS 27 IVa (T4N3) 8.2 44 4f 26 92 87 8.0 8 131 296 A
5 74/B/F MF 11 IVa (T2N3) 8.6 42 2 43 92 89 4.0 9 489 389 D
6 60/W/F SS 40 III (T4N0) 11.0 15 1 63 70 67 6.0 14 85 297 D
7 64/W/F SS 26 IVa (T4N3) 4.7 20 6f 28 94 90 4.0 14 8 292 D
8 84/W/F SS 239 IVa (T4N3) 14.7 43 0 74 95 92 3.0 14 312 246 D
9 62/W/M SS 7 III (T4N1) 5.2 41 2 50 89 89 4.0 16 112 203 D
10 68/W/M SS 53 III (T4N0) 6.2 27 1 71 90 88 3.0 17 587 184 D
11 69/W/M SSe 15 IVa (T4N3) 15.2 65 2f 50 90 96 1.0 20 27 201 D
12 44/W/F SS 127 III (T4N1) 5.9 44 2 70 92 87 6.0 20 235 235 A
13 73/W/F MF 10 Ib (T2N0) 10.9 30 5f 19 92 10 7.0 22 2 198 D
14 52/W/M SS 92 IVa (T4N3) 107.6 95 1f 91 90 99 0.5 27 5 680 D
15 83/W/M MF 29 IVa (T2N3) 11.1 77 0 92 95 96 2.0 28 4 265 D
16 31/W/F SS 89 IVa (T4N3) 7.0 11 1 50 88 82 8.0 32 765 204 A
17 56/W/F SS 54 III (T4N1) 10.1 18 2 35 79 68 5.0 36 5 200 D
18 59/W/M SSe 83 IVa (T4N3) 7.0 32 1 35 73 76 4.0 55 5 335 D
19 83/W/F SS 9 III (T4N1) 10.7 8 0 37 88 83 6.0 44 9 307 A
20 72/W/M GSSd,e 334 IVa (T2N3) 10.2 11 49f 46 89 84 4.0 47 Ð 291 D
21 65/W/F SS 25 III (T4N1) 10.2 37 3f 45 75 76 5.0 48 1347 427 D
22 75/W/M SS 31 III (T4N1) 16.7 52 3f 72 82 84 1.0 52 242 308 D
23 90/W/F SS 58 IVa (T4N3) 8.2 26 6f 38 78 74 5.0 55 208 211 D
24 79/W/M SS 30 III (T4N1) 8.5 45 2 58 90 82 3.0 56 227 183 D
25 81/W/F SSe 4 III (T4N1) 8.0 14 0 17 13 85 5.0 58 1 277 D
26 70/W/F SS 34 III (T4N0) 32.9 88 0 43 92 93 2.0 60 1 650 D
27 72/W/F MF 42 IVa (T2N3) 16.0 32 1 33 92 90 4.0 63 197 168 D
28 74/B/F SS 67 III (T4N1) 12.2 22 7f 19 67 63 6.0 65 39 314 A
29 86/W/M MF 50 IVa (T2N3) 8.4 20 1 41 71 66 6.0 67 3 287 D
30 60/B/M SS 88 IVa (T4N3) 35.0 82 4f 43 83 84 1.0 68 113 272 D
31 73/W/F SS 117 III (T4N0) 15.3 29 4f 34 88 83 8.0 71 5244 184 A
32 80/W/F SS 56 III (T4N0) 9.3 38 2 41 83 79 8.0 72 8 289 D
33 80/W/M SS 10 IVa (T4N3) 10.4 57 1 85 82 88 1.0 77 13 602 D
34 49/W/M SS 45 III (T4N1) 4.4 31 1 61 88 81 8.0 81 29 338 A
35 60/B/F SS 97 IVa (T4N3) 5.9 50 3 27 83 76 7.0 83 153 195 D
36 54/B/F SSe 128 IVa (T4N3) 4.7 22 4 21 67 55 0.5 85 42323 258 D
37 79/W/F SS 9 IVa (T4N3) 7.4 24 0 57 89 80 8.0 86 23 363 D
38 66/W/M SS 207 IVa (T4N3) 4.9 22 1 57 89 85 5.0 87 175 225 D
39 78/W/M SSe 36 IVa (T4N3) 26.7 73 2f 53 98 92 6.0 87 Ð Ð D
40 73/W/F SS 39 III (T4N0) 9.6 39 1 48 85 82 8.0 90 38 214 A
41 79/W/M SS 12 III (T4N1) 22.6 60 1f 29 95 7 3.0 97 293 212 D
42 84/W/F SS 19 IVa (T4N3) 26.6 69 2 92 96 97 1.0 99 1 276 A
aData correspond to time that CD4/CD8 ratio was 10 or more on ¯ow immunophenotyping of blood lymphocytes. Patients ranked according to percentage of CD7
expression by lymphocytes. Normal ranges for reference laboratory: White cell count (WBC) = 4.8±10.8 K per mL; Lymphocyte (LY) and eosinophil (EO) count on WBC
differential count = 19±48% and 0±7%, respectively; Percentage of normal lymphocytes expressing CD3, CD4, and CD8 = 68±82%, 35±55%, and 19±37%, respectively;
IgE = 14±122 U per liter; LDH = 0±220 U per liter; A/R/S, age, race, and sex of patient; SS, SeÂzary syndrome; MF, MF with SeÂzary cytemia; GSS, SeÂzary syndrome
with features of granulomatous slack skin disease; DUR, duration of disease; NR, PR, or CR, no response, partial response, or complete response; LS, last status; A, alive,
D, deceased; LDH, lactic dehydrogenase.
bMonths from onset of disease manifestations to ¯ow study.
cStatus as of August 2000.
dSeÂzary syndrome with sarcoidal tissue reaction.
eSeÂzary syndrome preceded by MF.
fAbsolute eosinophil count greater than 250 mm3.
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and mean %CD57 6 SD, 7.4 6 10.1) and below the normal
laboratory range in 14 of 23 (61%) and 20 of 23 (87%) cases,
respectively. The percentage of blood lymphocytes expressing CD7
in our cases ranged widely from 6% to 99% (median, 53.5%;
mean 6 SD, 48.8% 6 29.6, Table I). A plot of CD7 expression
against the expected normal distribution did not demonstrate a
signi®cant deviation (Fig 1); however, the distribution of CD7
expression did deviate from a normal distribution if the analysis was
restricted to 32 patients with classic SS, i.e., exclusion of patients
without generalized erythroderma or patients with secondary SS
that developed in patients with MF (Kolmogorov±Smirnov
normality test, p = 0.04). Nevertheless, a bimodal distribution of
cells that were either CD7± or CD7+ was not apparent for either
circumstance. When correlated directly against other clinical or
laboratory parameters using the Spearman correlation test, the
number of CD7+ cells correlated weakly to the number of CD16+
cells (39 cases, rho = +0.361, p = 0.02), CD57+ cells (31 cases,
rho = +0.402, p = 0.03), and CD38+ cells (31 cases,
rho = +0.448, p = 0.01).
Because CD7 is also expressed on essentially all normal CD8+ T
cells and natural killer cells, and because a signi®cant positive
association was found between the number of CD7+ cells and the
number of CD16+ and CD57+ cells that are markers expressed on
natural killer cells, we investigated the extent to which these non-
Table II. Comparison of ¯ow immunotyping of blood and LN from patients with the leukemic phase of CTCL
PT Tissue Date DXa PCR
Percentage of lymphocytes
CD7 CD16CD2 CD3 CD4 CD8
2 Blood 3/21/90 13.5/54/44 + 90 82 88 1 6 3
LN 3/30/90 LN3 + 67 57 59 4 23 1
3 Blood 2/5/91 15.2/43/46 + 95 92 80 15 24 5
LN 2/7/91 LN4 (M) + 63 74 71 5 9 5
4 Blood 5/15/96 8.2/44/26 + 45 92 87 8 8 2
LN 5/23/96 LN4 (S) + 42 51 65 12 11 0
5 Blood 3/9/95 8.6/42/43 + 79 92 89 4 9 4
LN 3/17/95 LN4 (L) ND 33 48 66 5 ND 5
9 Blood 4/23/91 5.2/41/50 ± 22 89 89 4 16 3
LN 4/24/91 LN4 (S) ± 22 61 57 6 23 2
Blood 11/18/94 15.0/53/32 + 16 96 96 2 2 0
LN 11/30/94 LN4 (M) + 18 30 27 18 4 1
10 Blood 5/16/95 5.3/16/12 + 81 70 24 49 45 17
LN 5/22/95 LN4 (L) ND 78 85 81 59 5 7
11 Blood 11/24/93 15.2/65/50 + 98 90 96 1 20 0
LN 12/16/93 GIb + 69 68 66 4 46 3
16 Blood 8/23/96 6.3/50/83 + ND 95 93 2 9 ND
LN 8/23/96 LN4 (M) + 43 24 15 4 14 1
18 Blood 9/6/90 7.0/32/35 + 76 73 76 4 55 6
LN 9/7/90 LN4 (S) + 62 68 65 2 55 0
19 Blood 5/28/96 6.6/16/39 + 54 70 68 7 60 10
LN 4/30/96 LN1 + 56 48 43 5 40 2
20 Blood 4/6/92 14.3/12/35 + 84 38 59 12 55 22
LN 4/14/92 LN4 (S) + 91 74 87 8 53 1
21 Blood 2/4/92 10.2/37/45 + 79 75 76 5 48 3
LN 1/7/92 LN2 + 48 45 46 3 45 0
Blood 7/25/95 12.7/51/34 + ND 88 87 1 40 5
LN 7/7/95 LN2 + 40 43 32 4 37 0
23 Blood 2/11/97 7.2/19/32 + 78 66 60 10 47 ND
LN 4/9/97 LN1 + 69 68 69 4 27 ND
27 Blood 5/8/90 16.0/32/33 + 93 92 90 4 63 2
LN 5/30/90 LN4 (S) + 73 78 83 3 65 0
28 Blood 5/31/95 12.2/22/19 ± 77 67 63 6 65 8
LN 6/27/95 LN2 ± 49 74 69 2 28 1
29 Blood 2/17/98 5.2/36/16 + 70 46 42 8 83 44
LN 2/19/98 LN4 (L) ± 92 90 93 2 37 5
33 Blood 5/30/95 10.4/57/85 ± 83 82 88 1 77 2
LN 6/21/95 LN4 (S) ND 63 67 88 2 59 0
37 Blood 7/22/98 8.7/33/nd + 92 88 82 1 88 ND
LN 7/24/98 LN4 (S) ND ND 70 74 1 70 ND
38 Blood 9/20/93 4.9/22/57 + 62 89 85 5 87 4
LN 9/21/93 LN4 (M) ND 58 61 63 4 53 2
39 Blood 7/2/96 26.7/73/53 + ND 98 92 6 87 ND
LN 7/3/96 c/w MFc ± ND 93 93 2 65 ND
41 Blood 7/10/98 22.6/60/29 + 96 95 7 3 97 2
LN 8/7/98 LN1 + 82 82 31 9 42 1
42 Blood 6/5/97 26.6/69/92 + 20 96 97 1 99 1
LN 7/3/97 LN3 + 32 92 87 2 93 0
+, positive; ±, negative.
aDX refers to routine diagnostic data obtained on tissue samples: For blood, the numbers are the total leukocyte count, percentage of lymphocytes on the differential
count, and the number of SeÂzary cells per 100 lymphocytes; for LN, the LN rating is based on the classi®cation scheme of Sausville et al (1985), and the cytologic appear-
ance of malignant in®ltrate in effaced (LN4) nodes is shown in parenthesis where S, M, and L refer to small cell, mixed cell, and large cell patterns as previously described
(Vonderheid et al, 1992).
bSarcoidal granulomatous in¯ammation.
cStudy on LN based on ®ne needle aspiration.
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CD4+ cells may have contributed to the observed CD7 results.
When raw CD7 values were corrected by subtracting the
percentage of CD8+ and CD16+ cells from the percentage of
CD7 for each case, excluding the two patients that were CD4±, the
correlation between raw CD7 and corrected CD7 values remained
very strong (n = 37, rho = 0.985, p < 0.001). Of interest, the
corrected CD7 values continued to correlate positively to the
percentage of CD16+ (n = 37; rho = + 0.437, p = 0.007),
CD38+ (n = 30; rho = 0.479, p = 0.008), and CD57+ (n = 30;
rho = 0.405, p = 0.03) cells.
The patient population was also divided into two cohorts based
on the estimated level of CD7 expression by CD4+ cells: a group of
19 patients with relatively low CD7 expression de®ned as
calculated CD7 expression on less than 50% of CD4+ cells, and a
group of 23 patients with more than 50% CD7 expression
(Table III). The four patients whose SS was preceded by typical
MF (patients 18, 25, 36, and 39) had leukemic cells that expressed
CD7. Comparison of various clinical and laboratory studies
between these two groups revealed that patients with lower CD7
levels had signi®cantly higher percentages of CD4+ and CD5+ cells,
and lower CD16+ and CD38+ cells. Because studies showing an
increased production of IL-4 and IL-5 by malignant T cells in SS
in vitro were performed on cells with a CD4+CD7± phenotype
(Vowels et al, 1992; Borish et al, 1993; Saed et al, 1994; Tendler et al,
1994; Dummer et al, 1996) and one case with a CD4+CD7+
phenotype had a Th1 cytokine pro®le (Yagi et al, 1996), we
wondered whether serum IgE level (via IL-4) and eosinophil count
(via IL-5) would correlate to the level of CD7 expression on CD4+
cells in our patients. In our series, serum IgE and absolute
eosinophil counts were increased over reference laboratory values
in 44% and 40% of studied patients, respectively. No signi®cant
difference in median serum IgE level or eosinophil counts,
however, was found between patients grouped according to level
of CD7 expression (Table III). Moreover, no correlation was
found between the calculated CD7 expression on CD4+ cells and
either serum IgE (rho = ±0.028, p > 0.8) or absolute eosinophil
count (rho = ±0.092, p > 0.5).
Similar results were found with SeÂzary patients studied at the
University of Turin except that the distribution of CD7 percent-
ages among 27 samples did vary signi®cantly from an expected
normal distribution (Fig 2). No difference from a normal distri-
bution was found, however, if the values were transformed to
log(CD7) (p > 0.2). The percentage of lymphocytes expressing
CD7 ranged from 2% to 93% (median, 23.0%; mean 6 SD,
33.8% 6 32.1%). When compared with American patients, the
Italian patients with SS had a signi®cantly higher percentage of
CD3+ and CD4+ cells, and a lower number of CD7+ cells (Mann±
Whitney test, p < 0.001). The difference in the CD4/CD8 ratio
and the percentage of CD8+ and natural killer cells between the
two series was not signi®cant. Consequently, the estimated level of
CD7 expression by CD4+ cells was markedly lower for Italian
patients than for our patients (Mann±Whitney test, p < 0.001).
Indeed, low CD7 expression on less than 50% of the CD4+ cells
was observed in 20 of 27 (74%) patients in the Italian series vs 18 of
42 (43%) of our series (Fisher's exact test, p < 0.001). These
®ndings suggest that the patients studied at the University of Turin
may have had more advanced disease than our patients. The fact
that only 62% of our cases had an absolute SeÂzary cell count > 1000
supports this interpretation. These differences, however, remained
signi®cant even if the analysis was restricted to the 26 patients with
absolute SeÂzary cell counts > 1000 cells per mm3 in our series. The
reason for the observed difference in CD3, CD4, and CD7
percentages between the two patient populations is unclear, but
may re¯ect differences in diagnostic criteria and patient selection at
each center.
CD7 in LN Flow immunophenotyping was obtained on 24 LN
samples from 22 patients (Table II). Histologic evidence of LN
involvement (LN3 or LN4 rating) was found in 14 (58%) of the
specimens; however, no signi®cant difference was observed
between histologically involved vs uninvolved specimens in terms
of the percentage of various antibody-positive cells, including
Table III. Comparison of laboratory results on patients
with the leukemic phase of CTCL. According to estimated
level of CD7 expression by CD4+ lymphocytes
Marker/testb
Expression of CD7 by CD4+ cellsa
Low (n = 19) High (n = 23) p-valuec
Duration (mo) 48.9 6 56.4 69.1 6 74.6 0.193
Lymphocyte count
(K per mL)
12.8 6 25.4 6.9 6 8.6 0.879
Eosinophil count
(per mL)
435 6 765 491 6 1037 0.820
SeÂzary count (%) 53.1 6 21.6 44.5 6 18.7 0.172
CD2 (%) 79.2 6 21.0 78.0 6 20.6 0.600
CD3 (%)d 88.6 6 6.3 84.2 6 9.1 0.088
CD4 (%)e 85.9 6 8.9 80.5 6 9.9 0.045
CD5 (%) 89.9 6 5.9 83.3 6 11.8 0.033
HLA-DR (%) 11.8 6 9.2 20.2 6 19.2 0.212
CD25 (%) 2.4 6 3.6 6.8 6 9.3 0.058
CD16 (%) 2.9 6 3.3 6.0 6 4.0 0.007
CD38 (%) 9.1 6 6.7 19.3 6 15.7 0.020
CD71 (%) 7.6 6 6.9 10.7 6 15.8 0.984
CD57 (%) 6.9 6 13.1 7.8 6 6.0 0.084
IgE (U per liter) 197 6 242 2402 6 9219 0.833
LDH (U per liter) 307 6 134 299 6 124 0.784
aThe level of CD7 expression within the CD4+ cell population is calculated
from one-color ¯ow immunophenotyping as: (%CD7 ± %CD8 ± %CD16) 4
%CD4 3100. Low and high level of CD7 expression is de®ned as < 50% CD7
(n = 19) and > 50% CD7 (n = 23) expression by CD4+ cells, respectively.
bValues expressed as mean 6 1 SD.
cDifference tested by Mann±Whitney test.
dOne patient with CD3± phenotype excluded.
eTwo patients with CD4± phenotype excluded.
Figure 1. Distribution of CD7 expression in leukemic phase
CTCL studied at MCP Hahnemann University. The percentage of
CD7 expression by blood lymphocytes of 42 patients with leukemic
phase of CTCL does not deviate signi®cantly from the expected value
of a normal distribution (Kolmogorov±Smirnov distribution, 0.127;
p = 0.09).
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CD7+ cells. This result indicates that quantitation of T cell subsets
may not be a reliable way to determine the degree of histologic
involvement in LN. Moreover, comparison with blood samples
obtained at or near the time of the LN sampling indicated that a
signi®cantly strong correlation exists between the percentage of
CD2+ cells (rho = 0.68) and CD7+ cells (rho = 0.77), but not for
CD3+ and CD4+ cells. Also a strong correlation was found
between the estimated level of CD7 expression on CD4+ cells
(rho = 0.66). This ®nding suggests that the distribution of
malignant T cells in peripheral LN and the blood in SS is
comparable.
Serial observations Multiple ¯ow studies that were obtained at
least 6 mo apart were available on 30 patients. In 20 patients the
CD4/CD8 ratio was greater than 10 on the initial ¯ow study, and
in the remaining 11 patients the CD4/CD8 ratio was subsequently
recorded as 10 or more 6±30 mo after the initial study. For patient
3, high numbers of CD8+ cells on the initial ¯ow study masked the
tumor phenotype, but the CD4+CD7± phenotype became apparent
and the CD4/CD8 ratio exceeded 10 on later blood studies with
progression of disease and also by immunophenotyping on an
involved LN obtained as part of the initial staging evaluation
(Table IV). In other patients with high CD4/CD8 ratios, the
number of CD8+ cells generally remained less than 10%
throughout the clinical course of disease, but in ®ve patients, the
numbers consistently increased to above 15%; this contributed to an
increase in CD7 percentage making the assessment of changes in
CD7 expression within the CD4+ population more dif®cult. For
this reason calculation of the level of CD7 expression on CD4+ was
found to be useful to estimate the percentage of CD4+CD7+ cells
when dealing with single parameter results.
The calculated level of CD7 expression by CD4+ cells changed
from CD7+ to CD7± in some patients over time (Table IV). Of 17
patients with evidence of CD7 expression on more than 50% of
CD4+ cells initially, subsequent studies showed an eventual
predominance of CD4+CD7± cells in nine patients, often associated
with clinical evidence of disease progression. The remaining eight
patients retained the CD7+ phenotype. Conversely, none of the 13
patients with CD7 on less than 50% of CD4+ cells on initial studies
developed a CD4+CD7+ cell phenotype. No signi®cant difference
in duration of follow up was found among these three subgroups of
patients.
In patients 29, 34, and 37, a discrete subset of large CD4+ cells,
representing 17%, 19%, and 41% of cells in the lymphocyte gate,
respectively, were detected on the basis of forward scatter (Fig 3).
For two patients (nos 34 and 37), the phenotype of these cells was
the same as the smaller cells (both CD7+), whereas for patient 29
the large cell component was CD4+CD7± and the small cell
component was CD4+CD7+. In one other patient (no. 4), a small
subpopulation of CD4+CD8+CD7± cells was detected in one
study, but then disappeared following a course of chemotherapy.
With regard to survival, the clinical and laboratory parameters
that correlated signi®cantly to survival on univariate analysis were T
and N ratings (p = 0.002 and p = 0.019, respectively), age
(p = 0.017), total leukocyte count (p < 0.001), percentage and
absolute lymphocyte count (p = 0.041 and p < 0.001, respect-
ively), absolute eosinophil and SeÂzary cell counts (p = 0.034 and
p = 0.002), but not their percentages, and serum lactic dehydro-
genase (p = 0.029). None of the lymphocyte markers, including
CD7 expression (p > 0.7) correlated signi®cantly with survival in
this subset of patients.
DISCUSSION
The patients in this series were selected to meet recently
recommended ¯ow immunophenotypic criteria for blood involve-
ment in SS, namely an increase in CD4+ cells with a CD4/CD8
ratio of 10 or more with evidence of a T cell clone in the blood
Figure 2. Distribution of CD7 expression in leukemic phase
CTCL studied at the University of Turin. Compared with the results
shown in Fig 1, the distribution of CD7 expression by blood
lymphocytes of 27 patients with SeÂzary syndrome with CD4/CD8
ratio = 10 who were studied at the University of Turin shows a greater
proportion of cases with low CD7 expression (Kolmogorov±Smirnov
distribution, 0.127; p = 0.009).







by CD4 (%)bSeÂzary CD3 CD4 CD8 CD7 CD16
3 11/12/90 1288 20 86 38 57 73 7 17
2/5/91 6536 46 92 80 15 24 5 10
6/26/91 18536 30 91 89 5 7 4 2
21 7/21/92 1350 47 67 73 3 63 ND 79
6/23/93 810 33 59 57 3 50 4 78
6/1/94 1026 33 66 60 6 56 10 76
6/25/96 4840 49 71 61 2 19 1 27
5/26/98 5880 48 97 98 1 2 2 10
aPatient 3 initially had high number of CD8+ cells that masked a CD4+CD7± tumor population that became more evident with disease progression; patient 21 showed
change from CD4+CD7+ predominant phenotype to a CD4+CD7± phenotype.
bLevel of CD7 expression by CD4+ cells calculated as: (%CD7 ± %CD8 ± %CD16) 4 %CD4 3100.
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(Willemze et al, 1997). Our observations indicate that CD7
expression on malignant T cells varies widely among cases of
leukemic CTCL and do not support the prevailing concept that SS
cases occur as two distinct subgroups, i.e., CD4+CD7+ or
CD4+CD7±, that arise as the consequence of an expanded subset
of CD4+ cells.
Haynes et al (1981) using the antibody 3A1, were ®rst to report
that malignant T cells of SS were often CD7 negative; however,
since then a CD4+CD7+ phenotype has been reported in
approximately one-third of cases of SS (Bogen et al, 1996;
Bernengo et al, 1998). With the availability of two-color
immunophenotyping, Harmon et al (1996) found that the
percentage of CD4+CD7± cells ranged widely (9±92%) for 18
patients with SS de®ned as SeÂzary cell count of more than 1000 per
mm3. In the series reported by Jakob et al (1996), the percentage of
CD4+CD7± cells ranged from 26% to 96% (70.9 6 26.9%,
mean 6 SD) for nine patients with CTCL at stage III/IV (all
with CD4/CD8 ratio > 10). Of three patients with a CD4/CD8
ratio more than 10 studied by Bogen et al (1996), the percentage of
CD4+CD7± cells was 70%, 90%, and 95%. Dummer et al (1996)
found the percentage of CD4+CD7± cells ranged from 30% to 65%
(mean, 51%) in eight patients with SS de®ned by an absolute SeÂzary
cell count of more than 1000 per mm3 and an elevated CD4/CD8
ratio. Scala et al (1999) used three-color immunophenotyping to
study six patients with SS, all with absolute SeÂzary cell counts
exceeding 2000 per mm3. The mean percentage of
CD3+CD4+CD7± cells was 88.7% with a large SD of 23.6%.
Finally, Rappl et al (2001) found that CD7 was uniformly lost on
more than 98% of Vb+ cells in seven patients with SS de®ned on
the basis of SeÂzary cell counts exceeding 1000 per mm3. These
observations and our ®ndings indicate that the level of CD7
expression by malignant T cells varies greatly among cases of SS
de®ned with other criteria.
Several explanations may account for the CD7 variability
observed among patients with SS. The ®rst possibility is that the
expanded CD4+ T cell population in SS consists of a heterogeneous
mixture of normal and malignant cells, and that the apparent level
of CD7 expression in a given patient re¯ects the relative numbers
of these cells. According to this hypothesis, if malignant T cells in a
particular case are uniformly CD7 de®cient, then a relatively high
level of CD7 expression in the blood can occur only when normal
CD4+CD7+ cells are markedly increased relative to the malignant
cell population. In this regard, patient 29, who had 66% CD4+ and
67% CD7+ cells overall (calculated level of CD7 on CD4+ cells was
85%), had evidence of a small population (17% of the total
lymphocytes) of abnormal large CD4+CD7± lymphocytes by
forward scatter. This observation indicates that CD4+CD7±
malignant cells potentially may be masked by large numbers of
nonmalignant CD4+CD7+ cells. In this regard, it is worth noting
that patient 3 is an example of a patient with SS in which the
malignant CD4+CD7± cells in the blood were initially masked by
large numbers of reactive CD8+ cells. Conversely, if malignant T
cells uniformly express CD7, then a low level of CD7 overall can
occur only when relatively high numbers of normal CD4+CD7±
cells are present in the blood. Lacking a speci®c marker of tumor
cells such as anti-idiotypic antibody (Bigler et al, 1983), we can
provide no direct evidence by ¯ow cytometry to indicate that such
a circumstance may occur. The quantitative SeÂzary cell count,
which provides an inexact measure of blood tumor burden,
correlated poorly with both raw (rho = ± 0.064) and corrected
(rho = ± 0.101) CD7 percentages even though it did correlate
signi®cantly with the percentage of CD4+ cells (rho = 0.36,
p = 0.023). If malignant CD4+ T cells were expressing CD7
uniformly among our patients, then a signi®cant correlation
between SeÂzary cell counts and CD7 percentages as well might
be expected. The lack of a signi®cant correlation supports the
interpretation that CD7 is not expressed uniformly on malignant
cells.
An alternative explanation to account for CD7 variability among
SeÂzary patients is that CD7 expression by individual malignant T
cells is not uniform, and that the overall level of CD7 expression in
a particular patient re¯ects the relative numbers of tumor cells that
may be CD7+ or CD7±. There is some support for this
interpretation. First, Ginaldi et al (1996) performed quantitative
measurements on CD7 molecule expression in ®ve patients with
SS. In two patients CD7 was undetectable, and in the other three
cases that expressed CD7, the mean number of CD7 molecules per
cell ranged widely. Indeed, the mean number of CD7 molecules
per cell in SS was lower than the range for normal T cells in one
case and above the range in one case. Secondly, for cases of SS
reported in the literature in which both a Vb antibody and CD7
were used to characterize malignant cells, the level of CD7
expression on Vb+ cells varied in some cases. An excellent
correlation between observed Vb and CD7 reactivity was found in
10 CD7± cases reported by Bogen et al (1996) and Rappl et al
(2001), and the CD7+ case reported by Yagi et al (1996); however,
Dummer et al (1999) reported that CD7 was expressed in at least
35% of Vb+ cells from three patients with SS who had high
percentages of CD4+CD7± in the blood. Thus, CD7 expression
seems to vary on malignant T cells in at least in some instances.
What biologic phenomenon underlies the apparent variable
expression of CD7 by malignant T cells in SS and other leukemic
forms of CTCL? One possibility to be considered is that the level of
CD7 expression is related to the activation state of the cells. When
normal T cells are stimulated in vitro, the level of CD7 expression
increases in T cells that express CD7 either strongly and weakly
whereas neither CD7 nor CD7mRNA is induced in normal
CD4+CD7± cells (Reinhold et al, 1993). In this regard, Kadin et al
(1984) noted that CD7 expression remained low on CD7±
malignant T cells of two patients with SS that were cultured in
the presence of phorbol ester for 5 d. Yagi et al (1996), however,
observed that a subpopulation of Vb17+CD7+ SeÂzary cells
decreased expression of CD7 when stimulated with concanavalin
A, but not staphylococcal enterotoxin B. These authors proposed
that SeÂzary cells are continuously stimulated in vivo to express high
levels of CD7, but an alternative explanation needs to be
considered. Reinhold et al (1996; Reinhold and Abken, 1997)
observed that when normal CD4+CD7+ T cells are stimulated
repeatedly via CD2 or CD3 in vitro, the number of CD7± cells
increases, suggesting that the CD7+ to CD7± conversion occurs in a
subset of CD4+ T cells as a differentiation event in the late immune
response. It also is of interest that the cerebriform nucleus that
Figure 3. Dot plot shows two lymphocyte populations in SeÂzary
syndrome. Two populations of malignant lymphocytes are identi®ed on
the ¯ow scattergram for patient 37 (small cells in the box designated by
the S arrow, large cells in the box designated by the L arrow). The large
cell component represents 40.6% of all lymphocytes.
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characterizes SeÂzary cells can be induced in normal lymphocytes via
stimulation of the TCR/CD3 complex and to a lesser extent CD2
(Reinhold et al, 1994).
Normal CD4+CD7± cells, which are absent in cord blood,
increase progressively during life (Kukel et al, 1994). The increase
in CD4+CD7± cells occurs with an increase in the proportion of
CD45RO+RA± ``memory'' T cells that also express activation
markers (HLA-DR+, CD25+, and CD71+) and CD57 within the
CD4+CD7± population. Because malignant T cells typically have
the CD45RO+ phenotype, one might expect to ®nd a higher
proportion of cells expressing activation markers in patients with
relatively low levels of CD7 expression on CD4+ cells. In this
regard, Scala et al (1999) found a high level of expression of the
activation markers CD60 and CD27 on CD4+ cells from six
patients with SS. Of interest, three of these patients showed a
bimodal distribution of CD3 into CD3bright (normal) and CD3dim
(atypical) subsets. The CD3dim cells were CD7±CD60+, whereas
the converse was found for the CD3bright cells. Three other patients
had two lymphoid populations based on cell size (similar to three of
our patients). The larger cells were CD7±CD60+ and the smaller
cells CD7+CD60±. These observations show that T cells in the
blood of SeÂzary patients can be quite heterogeneous in terms of
both CD7 expression and activation markers.
In our series, we observed somewhat lower levels of activation
markers in SeÂzary patients with low CD7 expression (Table III).
In fact, a statistically signi®cant positive correlation rather than a
negative correlation was actually observed between the calculated
level of CD7 expression on CD4+ cells and CD38 and CD57.
Furthermore, the possibility that malignant T cells may aberrantly
express low levels of natural killer cell markers CD16 (and CD57 as
well) was raised by the observed positive association between CD16
and the calculated level of CD7 expression on CD4+ cells, which
was derived by subtracting CD8 and CD16 from CD7. Additional
three-color ¯ow studies that combine CD4, CD7, and CD16 are
required to substantiate this observation.
Based on the above observations, it seems plausible that the level
of CD7 expression on malignant T cells (and perhaps the
cerebriform nucleus that characterizes SeÂzary cells) could be the
consequence of sustained immunologic stimulation in vivo that
converts a proportion of malignant T cells from CD7+ to CD7±. In
contrast to other peripheral T cell lymphomas and leukemias that
retain CD7, the loss of CD7 on the malignant T cells of CTCL
could be the consequence of ``memory'' cells programmed to home
into the skin where chronic immunologic stimulation may occur.
Consistent with this hypothesis is the observation that most (nine of
17) patients in our series whose tumor cells expressed CD7 on
more than 50% of CD4+ cells eventually became CD7± later in the
course of disease. Conversely, none of the patients with a
predominance of CD4+CD7± cells on initial studies subsequently
developed a CD4+CD7+ cell phenotype. The discrepancy between
the CD4+CD7+ and CD4+CD7± phenotype of small and large
tumor cells, respectively, in the blood of patient 29 discussed above
might also be explained by this mechanism. On the other hand, if
chronic antigenic stimulation results in the progressive loss of CD7
on malignant T cells, then a signi®cant negative correlation might
be expected between duration of disease and the level of CD7
expression on CD4+ cells, but this was not observed in our patients.
With regard to the immunobiologic implications of CD7
expression by malignant T cells, most studies indicate that the
usual cytokine secretion pro®le in SS consists of low Th1 cytokines
(IL-2 and IFN-g), and increased Th2 cytokines (IL-4, IL-5, and IL-
10). Exceptions, however, occur in almost all series (Bigler et al,
1994; Saed et al, 1994; Tendler et al, 1994; Dummer et al, 1996).
This indicates that malignant CD4+ cells in SS are not functionally
homogeneous in terms of cytokine production. Although CD7
expression correlated with the Th1 cytokine pro®le in the case
reported by Yagi et al (1996), no consistent difference in cytokine
mRNA expression was found between CD7+ and CD7± subsets in
®ve cases of SS studied by Dummer et al (1999).
Our observations did not reveal a signi®cant correlation between
the level of CD7 expression on malignant T cells and either
eosinophil counts or serum IgE levels. In addition, two other
studies found no correlation between IL-4 and serum IgE levels
(Vowels et al, 1992; Tendler et al, 1994). The reason for this lack of
association is unclear. In order for B cells to undergo an isotopic
switch from IgM to IgE, two signals are required: stimulation of the
IL-4 receptor by IL-4 followed by binding of CD40 to its ligand
(Bacharier et al, 1998). Bigler et al (1994) observed that CD40L is
not expressed constitutively by circulating SeÂzary cells, but when
stimulated by phorbol myristate acetate-ionomycin but not
phytohemagglutinin alone, CD40L is expressed by cells from
eight of 10 cases. Moreover, CD40L expression on stimulated
SeÂzary cells of some patients persisted, suggesting a defect in
downregulation of CD40L. Patients whose cells could be stimu-
lated to express CD40L were more likely to have elevated serum
IgE levels. Finally, SeÂzary cells could be induced to secrete IL-4
when stimulated with phorbol myristate acetate-ionomycin, but
not phytohemagglutinin. These observations suggest that activation
of malignant T cells in tissues such as the skin may provide the
necessary costimulus of CD40L expression in the presence of
increased IL-4 production by Th0/Th2 malignant cells.
In conclusion, our hypothesis is that persistent antigen stimu-
lation in vivo leads to loss of CD7 expression on some malignant T
cells analogous to what has been proposed to occur normally with
aging. In this regard, loss of CD7 is in effect a normal differentiation
phenomenon occurring with malignant T cells. Similar mechan-
isms may account for the observed association between lack of CD7
expression and the number of cells with cerebriform nucleus that
characterizes SS.
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